论文部分内容阅读
目的:了解血清红细胞生成素(EPO)水平在缺铁性贫血患者治疗前后的变化及其临床意义。方法:采用酶化学发光法和电化学发光免疫分析法(ECLIA)分别检测37例初诊缺铁性贫血患者治疗前及治疗1个月、2个月和3个月血清EPO的水平及铁蛋白的含量。以30例健康体检者作为正常对照。结果:1缺铁性贫血患者治疗前组、治疗1个月组及治疗2个月组血清EPO水平均高于正常对照组(P<0.05),治疗后各组的sEPO水平均低于治疗前组,随着贫血情况的纠正血清EPO水平逐渐降低,而治疗3个月组与正常对照组sEPO水平差异无统计学意义(P>0.05);缺铁性贫血患者治疗前后的铁蛋白含量均较正常对照组降低(P<0.05),治疗后各组的血清铁蛋白含量均较治疗前组增高,而治疗后各组间血清铁蛋白含量相比差异无统计学意义(P>0.05);2缺铁性贫血患者治疗前后logEPO与血红蛋白呈显著负相关,而缺铁性贫血患者的血清铁蛋白含量,仅在治疗前与血红蛋白含量呈正相关(r=0.449,P=0.005),治疗后各组及正常对照组的铁蛋白含量与血红蛋白均无相关性;3重度贫血组的血清EPO水平明显高于轻、中度贫血组,随着贫血的加重血清EPO水平逐渐升高。结论:EPO参与了红系造血过程,能反映贫血程度,其对贫血的敏感性高于血清铁蛋白,对缺铁性贫血患者评估病情、观察疗效、判断预后均有重要的临床价值。
Objective: To investigate the changes of serum erythropoietin (EPO) levels in patients with iron deficiency anemia before and after treatment and its clinical significance. Methods: Enzyme chemiluminescence and chemiluminescence immunoassay (ECLIA) were used to detect the levels of serum EPO and the levels of ferritin in 37 newly diagnosed newly diagnosed patients with iron deficiency anemia before treatment, 1 month, 2 months and 3 months after treatment content. 30 healthy subjects as normal control. The serum levels of EPO in patients with iron deficiency anemia before treatment, 1 month after treatment and 2 months after treatment were higher than those in normal control group (P <0.05). After treatment, the levels of sEPO in each group were lower than those before treatment Group, with the anemia corrected serum EPO levels gradually decreased, while the treatment of 3-month group and the normal control group sEPO levels were no significant difference (P> 0.05); iron deficiency anemia patients before and after the treatment of ferritin were The level of serum ferritin in each group was higher than that in the control group after treatment (P <0.05), but there was no significant difference in serum ferritin levels between the two groups after treatment (P> 0.05) .2 There was a significant negative correlation between logEPO and hemoglobin before and after treatment in patients with iron deficiency anemia. Serum ferritin in patients with iron deficiency anemia was positively correlated with hemoglobin only before treatment (r = 0.449, P = 0.005). After treatment, There was no correlation between the level of ferritin and hemoglobin in the normal control group. The level of serum EPO in 3 severe anemia group was significantly higher than that in the mild and moderate anemia group. The serum EPO level increased with the increase of anemia. Conclusion: EPO is involved in erythrocytic hematopoiesis, which can reflect the degree of anemia. It is more sensitive to anemia than serum ferritin. It has important clinical value in assessing the disease, observing the curative effect and judging the prognosis of patients with iron deficiency anemia.